Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Nov;31(11):2523-2525.
doi: 10.1038/leu.2017.242. Epub 2017 Jul 28.

Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)

G Bug  1 , A Burchert  2 , E-M Wagner  3 , N Kröger  4 , T Berg  1 , S Güller  1 , S K Metzelder  2 , A Wolf  1 , S Hünecke  5 , P Bader  5 , J Schetelig  6 , H Serve  1 , O G Ottmann  7
Affiliations
Clinical Trial

Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)

G Bug et al. Leukemia. 2017 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

GB and OGO: honoraria for advisory board participation from Novartis; GB and NK: research support from Novartis; GB: travel grants from Novartis; the remaining authors declare no conflict of interest.

Figures

Figure 1
Figure 1
(a) Cumulative incidence of relapse and non-relapse mortality. (b) Overall survival. (c) Relapse-free survival. Kaplan–Meier curves are shown for all patients enrolled and calculated from the first dose of panobinostat. Symbols represent censoring times.
See this image and copyright information in PMC

References

    1. Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2006; 12: 4628–4635. - PubMed
    1. DeAngelo DJ, Spencer A, Bhalla KN, Prince HM, Fischer T, Kindler T et al. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia 2013; 27: 1628–1636. - PubMed
    1. Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov 2014; 13: 673–691. - PubMed
    1. West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 2014; 124: 30–39. - PMC - PubMed
    1. Tao R, de Zoeten EF, Ozkaynak E, Chen C, Wang L, Porrett PM et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 2007; 13: 1299–1307. - PubMed

Publication types